Institute of Cancer Research report finds patients with cancer face delays in accessing ‘innovative’ drugs

Researchers found higher the level of innovation (IN), longer it took to pass trials, licensing and appraisal for availability on NHS. Between 2000 and 2016, most innovative new drugs took 14.3 years vs. 13.5 years for medium-IN and 11.1 years for least innovative treatments.

PharmaTimes